NLRP3 and lymphoma: In order to further explore the role of NLRP3 inflammasome in B-cell lymphoma progression, they employed a murine lymphoma model by injecting subcutaneously A20 cancer cells into 4-week-old female BALB/C mice and treating them with the NLRP3-inhibitor MCC950 or with placebo.